B+
Bull case
25%
Probability
Target price
$0.32
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
ERNA
Ernexa TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive primary-source case is that management has linked pre-IND feedback, tech transfer, and a planned first-in-human path for ERNA-101, while the February 2026 financing reduced immediate cash pressure enough to pursue near-term preparatory work.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Clinical and manufacturing execution risk is still substantial because ERNA-101 remains preclinical and must complete manufacturing, IND-enabling work, IND submission, and trial initiation before the thesis can move beyond a monitoring setup.
Momentum
93
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.14 · Bull $0.32 · Bear $0.05Analysis 2026-05-01; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $30.00
Why
Momentum93 · Δ7d -
Value41 · Δ7d -0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Clinical and manufacturing execution risk is still substantial because ERNA-101 remains preclinical and must complete manufacturing, IND-enabling work, IND submission, and trial initiation before the thesis can move beyond a monitoring setup.
- • Liquidity risk remains high: the 10-K disclosed about $1.9 million of year-end cash, operating cash burn, and substantial-doubt going-concern language despite the February 2026 financing.
- • The bearish read is that listing compliance and financing still dominate the story: Nasdaq deficiency risk remains active, another reverse split is queued, the company remains preclinical, and the 10-K still carries going-concern language even after the February raise.
Catalyst clock
2026-05-03
Reverse split execution and Nasdaq listing outcome
Lead driver: Value · See fundamentals
Momentum
93
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-17.2
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 93.4 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-01. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.14
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.05
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$6.63M
Beta
6.47
Shares Out
1.63M
P/E (TTM) · Derived
-0.1
P/S (TTM)
9497.16
P/FCF (TTM) · Derived
-0.29
Rev YoY
-100.0%
EPS YoY
-77.6%
Gross Margin
-26100.0%
Op Margin
-918700.0%
Net Debt
-$1.39M
Current Ratio
2.01
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data